Core Viewpoint - Wan Jia Group (00401) reported a loss attributable to shareholders of HKD 712,000 for the six months ending September 30, 2025, despite a revenue increase of 2.4% to HKD 85.706 million, driven by growth in the blood dialysis business [1] Financial Performance - Revenue for the period was HKD 85.706 million, reflecting a year-on-year increase of 2.4% [1] - The company recorded a loss attributable to shareholders of HKD 712,000, compared to a profit of HKD 1.256 million in the same period last year [1] - Basic loss per share was HKD 0.127 [1] Business Segment Analysis - The increase in revenue was primarily driven by the growth in the blood dialysis business [1]

Core Points - The company reported a revenue of HKD 85.706 million for the six months ending September 30, 2025, representing a year-on-year increase of 2.4% [1] - The company recorded a loss attributable to shareholders of HKD 0.712 million, compared to a profit of HKD 1.256 million in the same period last year [1] - The basic loss per share was HKD 0.127 [1] - The increase in revenue was driven by the growth in the blood dialysis business [1]

Group 1 - The core point of the article is that Wan Jia Group (00401.HK) reported a revenue of approximately HKD 85.706 million for the six months ending September 30, 2025, representing an increase of about 2.40% compared to the same period in 2024, primarily due to increased revenue from its dialysis business [1] - The company reported a loss attributable to shareholders of approximately HKD 712,000 for the period, compared to a profit of approximately HKD 1.256 million in 2024 [1] - The basic and diluted loss per share for the period was approximately HKD 0.127 [1]

Financial Performance - The revenue for the six months ended September 30, 2025, was approximately HKD 85,706,000, an increase of about 2.40% compared to HKD 83,695,000 for the same period in 2024, driven by growth in the hemodialysis business[3] - The company reported a loss attributable to owners of approximately HKD 712,000 for the current period, compared to a profit of approximately HKD 1,256,000 in the same period last year[3] - Gross profit for the current period was approximately HKD 25,774,000, a decrease from HKD 26,433,000 in the prior year[4] - The company recorded a total comprehensive income of HKD 152,000 for the current period, a significant decrease from HKD 2,791,000 in the same period last year[4] - The operating profit for the period was HKD 795,000, while the loss for the period amounted to HKD 849,000, indicating a decline compared to the previous year's profit of HKD 1,322,000[27][29] - The group reported a loss attributable to owners of approximately HKD 712,000, compared to a profit of HKD 1,256,000 in the previous year[62] Cash and Liquidity - Total cash and cash equivalents as of September 30, 2025, were approximately HKD 18,918,000, down from HKD 24,083,000 as of March 31, 2025[3] - The net cash generated from operating activities was HKD 3,126,000, a significant decrease from HKD 11,159,000 in the previous year[16] - The financing activities resulted in a net cash outflow of HKD 8,444,000, contrasting with a net inflow of HKD 1,630,000 in the prior period[16] - As of September 30, 2025, cash and cash equivalents decreased to HKD 18,918,000 from HKD 32,062,000 at the end of the previous period[16] Revenue Segmentation - For the six months ended September 30, 2025, the total revenue from external customers was HKD 85,706,000, with HKD 25,617,000 from pharmaceutical wholesale and distribution, and HKD 60,089,000 from dialysis treatment and consulting services[27] - The financial performance in the pharmaceutical wholesale and distribution segment showed a revenue decrease from HKD 27,232,000 in the previous year to HKD 25,617,000[29] - The dialysis treatment and consulting services segment reported a revenue increase from HKD 56,463,000 to HKD 60,089,000, reflecting growth in this area[29] Assets and Liabilities - The total assets of the group as of September 30, 2025, were approximately HKD 108,159,000, compared to HKD 106,822,000 as of March 31, 2025[7] - Current liabilities increased to approximately HKD 30,599,000 from HKD 29,002,000 as of March 31, 2025[8] - The company’s total equity attributable to owners was approximately HKD 67,171,000 as of September 30, 2025, compared to HKD 66,882,000 as of March 31, 2025[7] - Trade receivables increased to HKD 32,252 million as of September 30, 2025, up from HKD 25,074 million as of March 31, 2025[39] - Trade payables increased significantly to HKD 16,525 million as of September 30, 2025, from HKD 6,896 million as of March 31, 2025[42] Employee and Operational Costs - The group’s employee costs, including directors' remuneration, rose to HKD 14,424 million for the six months ended September 30, 2025, compared to HKD 13,360 million in the previous year[32] - Selling and distribution expenses for the period were approximately HKD 15,793,000, an increase of about 4.76% from HKD 15,075,000 in the previous year[58] - Administrative expenses for the period were approximately HKD 9,186,000, an increase of about 1.44% from HKD 9,056,000 in the previous year, primarily due to increased salary expenses[59] Dividend and Shareholder Information - The board of directors did not recommend the payment of an interim dividend for the current period, consistent with the previous year[3] - The company has not held any distributable reserves for shareholders during the reporting period, as per applicable laws in the Cayman Islands[15] - The group has not proposed any interim dividend for the period, consistent with the previous year[45] Stock Options and Equity - A total of 80,793,054 stock options have been granted under the 2013 stock option plan, with 14.42% of the company's issued shares represented by unexercised options[85] - The 2023 stock option plan allows for the issuance of 56,022,213 stock options, which accounts for approximately 10.00% of the total issued shares[86] - The company has granted 44,800,000 stock options to employees under the 2023 plan, representing 7.99% of the total issued shares[85] - The total number of stock options granted to directors amounts to 9,733,832, which is 1.74% of the total issued shares[85] Compliance and Regulatory Matters - The company announced a temporary suspension of the service agreement with Wuhua Medical Insurance Management Center for 61 days starting November 1, 2025, due to non-compliance issues[77] - The company is implementing corrective measures to comply with the notice from Wuhua Medical Insurance Management Center, including a comprehensive internal control review of the hemodialysis center's operations[76] - The company has verified that no similar non-compliance issues were found in other hemodialysis centers operated by the group[76] Corporate Governance - The audit committee, established in September 2013, includes three independent non-executive directors and is responsible for overseeing financial reporting and internal controls[103] - The remuneration committee, also established in September 2013, determines the specific remuneration of executive directors and reviews stock option grants based on performance without additional performance targets[105]

Core Viewpoint - Wan Jia Group (00401.HK) announced a board meeting scheduled for November 19, 2025, to discuss various matters including the unaudited interim results for the six months ending September 30, 2025 [1] Group 1 - The board will consider and approve the company's and its subsidiaries' unaudited interim results [1] - The board will discuss the potential declaration of an interim dividend, if applicable [1] - The board may consider suspending the transfer of company shares, if necessary [1] - The meeting will address any other matters that may arise [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 WANJIA GROUP HOLDINGS LIMITED 萬嘉集團控股有限公 司 於本公佈日期，董事會由一名執行董事王佳駿先生、一名非執行董事肖致信 醫生以及三名獨立非執行董事劉勇平博士、陳詠珊女士及許微女士組成。 1. 考慮及通過本公司及其附屬公司截至二零二五年九月三十日止六個月之 未經審核業績（「中期業績」），以及通過將於香港聯合交易所有限公司網 站及本公司之網站刊登有關中期業績之公佈； 2. 考慮派付中期股息（如有）； 3. 考慮暫停辦理本公司股份過戶登記手續（倘有需要）；及 4. 處理任何其他事項。 王佳駿 香港，二零二五年十一月三日 （於開曼群島註冊成立之有限公司） （股份代號：401) 董事會會議通知 萬嘉集團控股有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，董事會將 於二零二五年十一月十九日（星期三）於香港九龍廣東道25號海港城港威大廈1 期18樓01室舉行會議，以商議下列事項： ...

致：香港交易及結算所有限公司 公司名稱: 萬嘉集團控股有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00401 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | 本月底法 ...

Group 1 - The core point of the article is that Wanjia Group's subsidiary, Wuhua Yangke, has received a notice from the Wuhua County Medical Security Management Center regarding violations in prescription management and related regulations [1] - The notice indicates that Wuhua Yangke's blood dialysis center has deviated from standard medical prescription practices, leading to regulatory breaches [1] - As a result of these violations, the Wuhua Medical Security Management Center has implemented measures against Wuhua Yangke [1] Group 2 - As of October 28, 2025, Wanjia Group's stock closed at HKD 0.13, down 4.32%, with a trading volume of 39,600 shares and a turnover of HKD 5,075 [1] - The company has a market capitalization of HKD 77.87 million, ranking 9th in the pharmaceutical commercial sector [1] - Key financial metrics for Wanjia Group include a Return on Equity (ROE) of -37.38%, revenue of HKD 171 million, and a net profit margin of 1.58% [1]

Core Viewpoint - Wanjia Group's subsidiary, Wuhua Yangke, has received a notice from the Wuhua County Medical Security Management Center regarding non-compliance in its blood dialysis center operations, leading to a suspension of its service agreement for 61 days starting November 1, 2025 [1][2]. Group 1 - Wuhua Yangke's blood dialysis center was found to have deviated from standard medical prescription practices, violating relevant regulations [1]. - The management and legal representatives of Wuhua Yangke are required to attend a meeting with the Wuhua Medical Security Management Center to address the non-compliance issues [1]. - The service agreement with the Wuhua Medical Security Management Center will be suspended for 61 days, starting from November 1, 2025 [1]. Group 2 - During the suspension period, the Wuhua blood dialysis center will continue to operate but will not provide any services covered under the suspended agreement [2]. - Existing patients will be redirected to nearby dialysis centers or hospitals during the suspension [2]. - The company has confirmed that there are no similar non-compliance issues in its other dialysis centers and is implementing corrective measures to prevent future occurrences [2].

Core Viewpoint - Wanjia Group's subsidiary, Wuhua Yangke Kidney Dialysis Co., has received a notice from the Wuhua County Medical Security Management Center regarding non-compliance with medical prescription regulations, leading to a suspension of its service agreement for 61 days starting November 1, 2025 [1][2] Group 1 - Wuhua Yangke's dialysis center was found to have deviated from standard medical prescription practices, violating multiple regulations including the Prescription Management Measures and the Drug Administration Law of China [1] - The Wuhua Medical Security Management Center has mandated that the legal representative and management of Wuhua Yangke attend a meeting to address the non-compliance issues [1] - The service agreement with the Wuhua Medical Security Management Center will be suspended for 61 days, during which the dialysis center will not provide any services covered under the agreement [1][2] Group 2 - The company is taking the non-compliance issues seriously and will implement immediate corrective measures, including a comprehensive internal control review of the dialysis center's operations [2] - During the suspension period, the dialysis center will continue to operate but will only offer services outside the scope of the suspended agreement, with existing patients being redirected to nearby facilities [2] - The company believes that the limited operations during the suspension will not have a significant adverse impact on its financial condition, business, or daily operations [2]